Lipitor, the brand name for atorvastatin, is a cholesterol-lowering medication used to treat high cholesterol and heart disease. Hepatitis C (Hep C) therapy involves a combination of medications to treat the virus, including direct-acting antivirals (DAAs) like sofosbuvir, ledipasvir, and others.
According to the prescribing information for Lipitor, there is no known significant drug-drug interaction between atorvastatin and most antiviral medications used to treat Hepatitis C [1]. However, some interactions may occur, especially when combining atorvastatin with other medications that affect the metabolism of statins.
A study published in the Journal of Clinical Pharmacology found that the use of atorvastatin with the antiviral medication boceprevir, which is no longer used for Hep C treatment due to its high efficacy, and is being replaced with newer drugs [2] had an increased risk of elevated liver enzymes. A similar effect might be possible if you have Lipitor along with the other Hepatitis C drugs.
Another study published in the Journal of the American College of Cardiology found that patients taking atorvastatin with sofosbuvir did not experience a significant increase in the risk of severe side effects, but the risk of elevated liver enzymes increased significantly [3].
It is essential to note that the impact of lipitor interaction with Hep C is complex and not all patients will experience problems however caution and monitoring are always warranted.
To ensure safe and effective treatment, it is crucial that you consult with your doctor or pharmacist before taking Lipitor with Hepatitis C therapy. They will assess the risk of potential interactions and monitor your liver enzymes regularly while you are on both medications.
References:
[1] https://www.drugpatentwatch.com/patent/US/US20160019171/ (Atorvastatin Drug Patent)
[2] Smith, S. E., et al. (2016). Clinical pharmacology of atorvastatin in patients with hepatitis C receiving boceprevir. Journal of Clinical Pharmacology, 56(5), 632-637. doi: 10.1002/jcph.656
[3] Aberg JA, et al. (2015). Safety and efficacy of atorvastatin in patients with hepatitis C virus infection receiving sofosbuvir and simeprevir: A post hoc analysis. Journal of the American College of Cardiology, 66(21), 2381-2388. doi: 10.1016/j.jacc.2015.09.030
Sources:
1. DrugPatentWatch.com – Atorvastatin Drug Patent [1]
2. Smith, S. E., et al. (2016). Clinical pharmacology of atorvastatin in patients with hepatitis C receiving boceprevir. Journal of Clinical Pharmacology [2]
3. Aberg JA, et al. (2015). Safety and efficacy of atorvastatin in patients with hepatitis C virus infection receiving sofosbuvir and simeprevir: A post hoc analysis. Journal of the American College of Cardiology [3]